Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulatory Update
20 juin 2019 09h15 HE
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, June 20, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...